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Abstract
 
T cell recruitment to elicit contact sensitivity (CS) requires a CS-initiating process mediated by
B-1 cells that produce IgM, which activates complement to promote T cell passage into the tissues.
We now show that V
 
 
 
14i NKT cells induce B-1 cell activation likely by releasing IL-4 early
postimmunization. The CS initiation process is absent in J
 
 
 
18
 
 
 
/
 
  
 
and CD1d
 
 
 
/
 
 
 
 NKT cell–
deficient mice and is reconstituted by populations enriched for V
 
 
 
14i NKT cells. Transfers are
not effective if cells are derived from IL-4
 
 
 
/
 
 
 
 mice. Staining with specific tetramers directly
showed that hepatic V
 
 
 
14i NKT cells increase by 30 min and nearly double by 2 h postimmu-
nization. Transfer of immune B-1 cells also reconstitutes CS responses in NKT cell–deficient
mice. The B-1 cells act downstream of the V
 
 
 
14i NKT cells to restore CS initiation. In addition,
IL-4 given systemically to J
 
 
 
18
 
 
 
/
 
  
 
or CD1d
 
 
 
/
 
  
 
NKT cell–deficient mice reconstitutes elicitation of
CS. Further, splenocytes from immune J
 
 
 
18
 
 
 
/
 
 
 
 mice produce less antigen (Ag)-specific IgM
antibodies compared with sensitized WT mice. Together these findings indicate that very early
after skin immunization V
 
 
 
14i NKT cells are stimulated to produce IL-4, which activates B-1
cells to produce Ag-specific IgM, subsequently needed to recruit effector T cells for elicitation
of CS responses.
Key words: V
 
 
 
14i NKT cells • B-1 cells • contact sensitivity • liver lymphocytes • IL-4
 
Introduction
 
Contact sensitivity (CS) is an example of delayed-type hyper-
sensitivity (DTH) induced by haptens that conjugate to
self-protein Ags and peptides in the skin. CS is mediated by
local extravascular recruitment of Ag-specific circulating
CS effector T cells that cause inflammatory tissue swelling,
peaking 24 h after secondary skin Ag challenge.
To locally recruit sensitized T cells, an early 2-h initiating
response is required (1). This initiating response is due to
binding of Ag to specific IgM antibodies produced rapidly
postimmunization by B-1 B cells (2). Local Ag–IgM com-
plexes are generated leading to complement activation to
initiate elicitation of CS by locally generating C5a to activate
receptors (3) on mast cells (4, 5) and platelets (6, 7), resulting
in release of vasoactive TNF-
 
 
 
 (3, 8) and serotonin (4, 6, 9,
10). This stimulates endothelial expression of adhesion
molecules (ICAM-1 and VCAM-1) (8) needed to recruit
circulating CS effector T cells (11). These early events of
elicitation are called “CS initiation,” since they are required
to recruit CS effector T cells to mediate the 24-h component
of CS.
NKT cells participate early in immune responses, expressing
NK receptors and markers and a unique 
 
  
 
-TCR (12).
Mice dominantly express a conserved 
 
  
 
-TCR with invariant
V
 
 
 
14J
 
 
 
18 (formerly J
 
 
 
281) paired mainly with V
 
 
 
 8.2,
V
 
 
 
7, or V
 
 
 
2 chains (13). They are herein referred to as
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V
 
 
 
14i NKT cells or iNKT cells, to distinguish from other
NKT cells, and represent 30–40% of liver 
 
  
 
-T cells but
smaller numbers in lymphoid organs (12). iNKT cells are
restricted to recognizing Ags bound in the MHC class
I–like molecule CD1d expressed with 
 
 
 
2 microglobulin
on various APC (14). Ligand Ags are glycolipids such as
 
 
 
-galactosylceramide (
 
 
 
-GalCer) (15). The V
 
 
 
14i NKT
cells rapidly release cytokines, such as IL-4 or IFN-
 
 
 
, very
soon after TCR activation.
Here, we provide evidence that V
 
 
 
14i NKT cells are
important in the CS initiation process because they stimu-
late B-1 cells to produce IgM antibodies rapidly after im-
munization that eventually leads to local T cell recruitment
to elicit CS. Hepatic NKT cells are preferentially activated
to release IL-4, that together with immunizing Ag, coacti-
vate the B-1 cells. It is noteworthy that V
 
 
 
14i NKT cells,
like B-1 cells, are subpopulations of innate cells. The rapid
response in CS of B-1 cells and hepatic V
 
 
 
14i NKT cells,
both innate cells, illustrates their cooperative interaction
bridging innate and adaptive immune responses.
 
Materials and Methods
 
Mice.
 
Specific pathogen-free male CBA/J, female BALB/c, fe-
male CD1d
 
 
 
/
 
 
 
 (129/SvImJ), and WT controls were from The
Jackson Laboratory. Breeders of BALB/c J
 
 
 
18
 
 
 
/
 
  
 
mice (formerly
J
 
 
 
281
 
 
 
/
 
 
 
) were from Masaru Taniguchi (Chiba University, Chiba,
Japan), and BALB/c V
 
 
 
14 transgenics were from Albert Bendelac
(University of Chicago, Chicago, IL). Groups of four to five mice
at 6–12 wk of age were rested at least 1 wk under specific patho-
gen-free conditions. Experiments were performed according to
guidelines of the Animal Care and Use Committee at Yale.
 
Reagents.
 
Picryl chloride (PCl, TNP-Cl) (provided by Na-
calai Tesque, Inc.) was recrystallized twice and stored protected
from light. Kirin Laboratories provided 
 
 
 
-GalCer (16). A stock
solution at 220 
 
 
 
g/ml was diluted to 0.5–4 
 
 
 
g/ml in 0.5%
polysorbate-20 for injection in sterile pyrogen-free 0.9% NaCl
(Abbott Labs).
 
Immunization and Elicitation of CS.
 
Mice were contact sensi-
tized with 150 
 
 
 
l of 5% PCl in absolute ethanol and acetone (4:1)
on the shaved chest, abdomen, and rear footpads. CS responses
were elicited on day 4 by painting ears with 10 
 
 
 
l of 0.4% PCl in
acetone and olive oil (1:1). Sensitization was performed on days
 
 
 
1 and 0 in 129S3/SvImJ mice. Ear thickness was measured with
a micrometer (Mitutoyo) before challenge and then at 2 and 24 h
by an observer unaware of experimental groups. Increases in ear
thickness are expressed as the mean 
 
 
 
 SE 
 
 
 
 10
 
 
 
2
 
 mm.
 
Isolation of Sensitized T Cells from Immune LN and Spleen.
 
Mice were killed on day 4, and axillary and inguinal LNs and
spleens were processed to cell suspension used for transfers. To
remove B cells, anti–mouse CD19 mAb (0.5 
 
 
 
g/10
 
6
 
 cells) (BD
Biosciences) was added at 4
 
 
 
C for 45 min, followed by washing
and resuspension at 10
 
7 
 
cells/ml, and treated with 1 ml of 1:5 di-
luted rabbit complement (PEL-FREEZ) for 45 min at 37
 
 
 
C, fol-
lowed by extensive washing with cold PBS, and injected i.v. at
2–5 
 
 
 
 10
 
7
 
 cells/mouse.
T cells were isolated by magnetic bead depletion of non–T cells
using a Pan T Cell Isolation kit (MACS Miltenyi Biotec). Cells
from LNs and spleen were passed through 30 
 
 
 
m nylon mesh to
remove cell clumps, washed with degassed buffer (0.5% BSA, 2
mM EDTA, PBS pH 7.2), and stained with mixed biotinylated
 
antibodies to Mac-1, B220, DX5 (NK marker), and Ter-119
(erythrocyte marker). Then, cells were combined with antibiotin
microbeads at 4
 
 
 
C and passed through an LS column (10
 
8
 
 cells) in
a magnetic field of a MidiMACS separator. The columns were
washed four times, and then effluent cells were collected, centri-
fuged, counted, and analyzed by flow cytometry (99% TCR
 
 
 
 
 
),
resuspended in PBS, and injected i.v. at 2 
 
 
 
 10
 
7
 
 per mouse.
 
Liver Cell Preparation to Obtain Enriched Mononuclear Cells
(LMNCs).
 
After sacrifice, liver was PBS perfused via the portal
vein until opaque, then strained (70 
 
 
 
m; Becton Dickinson), re-
suspended in 40% isotonic Percoll (Amersham Biosciences), and
overlaid onto 60% isotonic Percoll. After centrifugation for 20
min at 900 
 
g 
 
at 25
 
 
 
C, liver mononuclear cells (LMNCs) were iso-
lated at the interface and the 40% Percoll and washed with RPMI
1640 (Life Technologies) plus 5% FBS (Gemini-Bio-Products).
Viability was 
 
 
 
90%, and 
 
 
 
2 
 
 
 
 10
 
6
 
 LMNCs were obtained per
mouse.
 
Flow Cytometry and Binding of Tetramers to iNKT Cell TCR.
 
PE-labeled tetramer mouse CD1d–
 
 
 
-GalCer complexes that
bind V
 
 
 
14i NKT cell receptors and “unloaded” control CD1d
without 
 
 
 
-GalCer were prepared (13). LMNCs were resus-
pended in PBS staining buffer containing 2% BSA and 0.02%
NaN
 
3
 
 and then incubated for 15 min at 4
 
 
 
C with blocking 2.4G2
anti-Fc mAb (BD Biosciences) and blocking neutravidin (Molec-
ular Probes). After washing, LMNCs were stained with a mixture
of FITC anti-TCR
 
 
 
 mAb (BD Biosciences) and PE-labeled
CD1d–
 
 
 
-GalCer tetramers at 25
 
 
 
C for 20 min and then washed
twice. Double tetramer and TCR
 
 
 
-positive cells were identified
using a FACS
 
®
 
 Vantage SE (Becton Dickinson). A minimum of
5 
 
 
 
 10
 
4
 
 events was acquired, and results were analyzed using Mac
CellQuest (Becton Dickinson).
 
Sorting of Immune Lymphoid B-1 Cells.
 
Spleen and LN cells
from 1-d PCl-sensitized donors were stained at 10
 
6
 
–10
 
7
 
/ml with
anti-CD5–cychrome, and anti-CD19–FITC (BD Biosciences) at
0.025 
 
 
 
g per 10
 
6
 
 cells for 30 min on ice and then washed with
RPMI. Stained cells were sorted to obtain 
 
 
 
 98% enriched
CD19
 
 
 
CD5
 
 
 
 B-1 cells, representing  1% of total cells, and 6.5  
104 B-1 cells were injected i.v. per mouse.
Enzyme-linked Immunospot (ELISPOT) Assay for Anti-TNP
IgM-producing Cells. Spleen and LN cells were from 4-d 5% PCl
immune mice and seeded in triplicate into 96-well filtration plates
with Immobilon-P membranes (Millipore) at 2   106 cells/well,
precoated with 50  l of TNP3-BSA (100  g/ml). Plates were in-
cubated overnight at 37 C, cells were discarded, and wells were
washed with PBS three times and three times with PBS contain-
ing 0.05% Tween-20, and incubated for 1 h at 25 C with 2  g/
ml of biotin-conjugated anti–mouse IgM mAb (BD Biosciences),
followed by incubation with streptavidin–horseradish peroxidase
(1:200; Vector Laboratories) for 1 h. Spots were developed by
using 3-amino-9-ethylcarbazole as substrate, the reaction was
stopped by washing, and wells were dried at 25 C in the dark.
Membranes were removed, stuck on glass slides, and spots were
enumerated under an inverted dissecting phase microscope and
expressed per organ.
Statistics. Statistics were performed using the paired two-tailed
Student’s t test. P   0.05 was taken as the level of significance.
Results
Defective Elicitation of CS in NKT Cell–deficient Mice
We evaluated CS responses in CD1d /  mice that are
NKT cell deficient because CD1d is the Ag-presentingCampos et al. 1787
molecule required for V 14i TCR  cells to develop in the
thymus (17). Contact-sensitized CD1d /  mice had signif-
icantly inhibited 24-h CS responses (Fig. 1 A, right, Group
C vs. A). Importantly, the 2-h initiating component of CS
was profoundly inhibited in CD1d /  compared with WT
mice (Fig. 1 A, left, Group A vs. C) and reduced to base-
line levels equivalent to nonimmunized and similarly PCl-
challenged controls (Fig. 1 A, left, Group C vs. B and D).
To determine if the major V 14i NKT cell population was
involved, CS responses were studied in J 18 /  mice spe-
cifically deficient in this subset. Again, we found defective
CS, with absent 2-h early responses (Fig. 1 B, left, Group
C vs. A) and significantly impaired 24-h late responses (Fig.
1 B, right, Group C vs. A), similar to findings in CD1d / 
(Fig. 1 A).
Liver Mononuclear Cells from WT Mice and Splenocytes from
V 14 Transgenic Mice Reconstitute Defective CS in J 18 / 
Mice. To confirm the role of V 14i NKT cells in CS re-
sponses more directly, we i.p. transferred nonimmune
WT LMNCs into NKT cell–deficient J 18 /  mice 1 d
before immunization. Transfer of 1–2   106 LMNCs
from nonimmune BALB/c mice resulted in reconstitu-
tion of 2- and 24-h CS ear responses in subsequently
immunized J 18 /  mice (Fig. 2 A, Group C vs. B),
whereas transfer of LMNCs from nonimmune J 18 / 
mice without V 14i NKT cells failed (Fig. 2 A, Group D
vs. B and C).
Since V 14i NKT cells can rapidly release IL-4 (12) and
IL-4 can act on B-1 cells (18, 19), we hypothesized that
V 14i NKT cells acted in CS by release of IL-4. To test
this hypothesis, we similarly transferred nonimmune
LMNCs from IL-4 /  mice that failed to reconstitute de-
fective CS responses in J 18 /  recipient mice (Fig. 2 A,
Group E) compared with J 18 /  mice transferred with
WT BALB/c LMNCs (Fig. 2 A, Group C). In contrast,
LMNCs from IFN-  /  mice fully reconstituted the 2-h
response (Fig. 2 A, left, Group F vs. B).
Figure 1. NKT-deficient mice have defective CS. (A) CD1d /  mice
(Group C) and WT CD1d /  controls (Group A) were skin sensitized
with 5% PCl and on day 4 were ear challenged with 0.4% PCl. Nonimmune
CD1d /  and CD1d /  (Groups D and B) controls were similarly ear
challenged. Ear swelling was measured at 2 h (left) and 24 h (right). The
results represent pooling from three different experiments each with three
mice per group. (B) J 18 /  mice (Group C) and WT BALB/c controls
(Group A) were sensitized and ear challenged. Nonimmune J 18 / 
(Group D) and BALB/c (Group B) controls were ear challenged similarly.
2- and 24-h ear swelling responses were measured. The results are from a
representative experiment with five mice per group.
Figure 2. Reconstitution of CS in J 18 /  mice by transfer of
LMNCs. (A) BALB/c (Group A) and J 18 /  mice (Groups B–F) were
sensitized, and 4 d later were ear challenged and responses were measured
at 2 and 24 h. 1 d before immunization, groups of J 18 / mice received
1–2   106 LMNCs i.p. from nonimmune BALB/c mice (Group C),
J 18 /  mice (Group D), IL-4 /  mice (Group E), or IFN-  /  mice
(Group F). Responses in each group represent the result from subtraction
of background ear swelling of a control nonimmune group challenged
similarly. The results are the pooling of three different experiments each
with four mice per group. 2-h response statistics: P   0.01, Group A vs.
B; P   0.01, Group C vs. E; **P   0.05, Group F vs. B. 24-h response
statistics: P   0.001, Group A vs. B; P   0.01, Group C vs. E; NS, not
significant, Group F vs. B. (B) BALB/c (Group A) and J 18 /  mice
(Groups B–E) were sensitized, ear challenged, and responses were measured
at 2 and 24 h. 1 d before, groups of J 18 / mice received LMNCs i.p.
from nonimmune WT BALB/c mice (Group C), or V 14 transgenic
mice (Group D), or splenocytes from V 14 transgenic mice (Group E).
Each transferred group received an equivalent number of V 14i NKT
cells according to the percentages of tetramer-positive T cells determined
previously. The response in each group represents the result from subtraction
of background ear swelling of a control nonimmune group challenged
similarly. The results are from a representative experiment with four mice
per group. 2-h response statistics: P   0.02, Group A vs. B; **P   0.01,
Group B vs. D and B vs. E. 24-h response statistics: P   0.005, Group A
vs. B; ***P   0.001, Group B vs. D; **P   0.01, Group B vs. E.V 14i NKT Cells Initiate Contact Sensitivity 1788
To test if V 14i NKT cells from spleen also could re-
constitute impaired CS in J 18 /  mice, we similarly i.p.
transferred nonimmune splenocytes or LMNCs from V 14
transgenic mice that have greatly increased V 14i NKT
cells compared with BALB/c. (Fig. 2 B). Equivalent num-
bers of V 14i NKT cells were transferred compared with
WT LMNCs, according to percentages of tetramer positive
T cells in the V 14 transgenic LMNCs (65%) and spleno-
cytes (51%). Results showed that either LMNCs or spleno-
cytes from V 14 transgenic mice reconstituted defective
Figure 3. Liver NKT cells are activated early after PCl skin sensitization. (A) CBA/J mice
were PCl skin sensitized or injected i.v. with 4  g  -GalCer. Separate groups of mice were
killed at 30 min, 1 h, 2 h, 5 h, or 24 h, and LMNCs were isolated and stained with FITC
anti-TCR  mAb and PE CD1d– -GalCer tetramers and analyzed by flow cytometry to
identify double positive V 14i NKT cells. Percentages were determined based on the analysis
of pooled LMNCs from four to five mice per group, except for 2- and 5-h points performed
twice. (B) Dot plots show the percentage of tetramer-positive T cells from a representative
experiment comparing nonimmune and 2-h skin immune CBA/J mice.
Figure 4. CS does not induce nonspecific binding of
tetramers to LMNCs. (A) Different groups of CBA/J
mice were PCl skin sensitized or i.v. injected with 0.5
 g of  -GalCer, and 4 h later LMNCs were obtained
and stained with CD1d- -GalCer tetramers or PE-
CD1d–unloaded tetramers to evaluate nonspecific
binding. We analyzed pooled LMNCs from four mice
per group. (B) Different groups of J 18 /  or CD1d / 
mice and appropriate WT controls were PCl sensitized,
and 2 h later LMNCs were obtained. The LMNCs
were stained to analyze V 14i NKT cells by flow cy-
tometry. The numbers indicate the percentages of
tetramer-positive liver TCR   cells analyzing pooled
LMNCs from four mice per group.Campos et al. 1789
CS responses in J 18 / mice similar to nonimmune
BALB/c LMNC NKT cells (Fig. 2 B, Group B vs. C–E).
Direct Stimulation of Liver V 14i NKT Cells by Skin Con-
tact Sensitization. We tested for a more direct connection
between cutaneous sensitization and V 14i NKT cells by
determining changes in the proportion of liver V 14i
NKT cells after skin immunization. PE-CD1d– -GalCer
tetramers were used to identify NKT cells in liver after PCl
skin painting by flow cytometry (13). As positive control,
we followed liver V 14i NKT cell levels after i.v. injection
of 4  g  -GalCer (13) that caused initial increases followed
by a rapid disappearance (Fig. 3 A).
Remarkably, cutaneous PCl immunization also rapidly
induced profound changes in liver V 14i NKT cells but
with very different kinetics (Fig. 3 A). By 30 min, V 14i
NKT cells rose from 36% to 48% (33% increase), and by
Figure 5. V 14i NKT cells increase in liver after CS but not LNs,
spleen, and peritoneal cavity. (A) CBA/J mice were PCl skin sensitized,
and 2 h later mononuclear cells from liver, peritoneal cavity, spleen, and
LNs were stained with FITC anti-TCR  mAb and PE CD1d– -GalCer
tetramers and analyzed by flow cytometry for the percentage of tetramer-
positive T cells compared with nonimmune mice determined by analysis
of pooled mononuclear cells from three mice per group. BALB/c (B) and
V 14 transgenic mice (C) also were PCl immunized, and 1 h later mono-
nuclear cells from the liver, peritoneal cavity, spleen, and LNs were
stained and analyzed by flow cytometry.V 14i NKT Cells Initiate Contact Sensitivity 1790
1 h rose further to 54% (50% increase), and peaked at near
doubling to 65% of T cells by 2 h (81% increase) (Fig. 3 B),
with a similar increase in total numbers of liver V 14i
NKT cells (not depicted). By 5 h, there was a decline to
58% and then to a normal level of 38% by 24 h.
Important negative controls showed that unloaded
CD1d tetramers without  -GalCer binding in the groove
did not nonspecifically bind to LMNCs from nonimmune
or  -GalCer–treated or PCl contact-sensitized mice (Fig. 4
A). Thus, binding depended on fully loaded tetramers con-
taining  -GalCer. Further, when the full tetramers were
used both nonimmune and untreated J 18 /  and CD1d / 
LMNCs, and those from sensitized J 18 /  and CD1d / 
mice, had no binding to remaining LMNCs in these mice
without NKT cells (Fig. 4 B, middle and right). Hence, CS
did not induce LMNCs to nonspecifically bind the tetra-
mers. In contrast, nonimmune BALB/c controls for J 18 / 
mice had 44% tetramer-positive cells in the liver, and non-
immune WT 129 controls for the CD1d /  mice had 11%
tetramer positive cells (Fig. 4 B, left). These control find-
ings support the specificity of the rapid increase in tetramer
binding to liver V 14i NKT cells in PCl contact-sensitized
WT mice (Fig. 3).
Comparison of NKT Cell Activation in Different Organs of
PCl Contact-sensitized Mice.  We questioned if the rise in
V 14i NKT cells directly after skin immunization occurred
preferentially in the liver. Thus, we used tetramers to ana-
lyze levels of V 14i NKT cells in spleen and also in other
sites of PCl contact-sensitized CBA/J mice at 2 h com-
pared with nonimmune controls. Again, a near doubling of
liver V 14i NKT cells occurred (Fig. 5 A, top), whereas
there were no increases in the spleen, peripheral LNs, or
peritoneal cavity after PCl skin immunization (Fig. 5 A).
To compare results at an earlier time point in another
strain, we similarly measured the levels of V 14i NKT cells
in BALB/c mice 1 h after skin immunization. Similarly,
only the hepatic V 14i NKT cells increased as a percentage
of    T cells, from 29% to 38% (Fig. 5 B, top), whereas
the other sites did not show any significant changes (Fig. 5
B). Further, nonimmune V 14 transgenic mice (BALB/c
background) with higher basal levels of V 14i NKT cells at
these various sites also had only increases in the liver from
65% to 85% after skin immunization, and not at the other
sites (Fig. 5 C).
Failure of CS Initiation Is the Cause of Defective CS Elicita-
tion in NKT-deficient Mice. The absent 2-h component of
CS in both NKT cell–deficient strains suggests defective
CS initiation because V 14i NKT cells are needed to acti-
vate the CS-initiating B-1 cells. Thus, we compared the
CS initiation process in 1-d PCl contact-sensitized recipi-
ent CD1d /  vs. WT mice. At this early time, the B-1 cells
are activated (2), but Ag-specific CS effector T cells are not
yet immunized (1, 2, 20, 21). We transferred syngeneic 4-d
PCl immune-isolated CS effector T cells that are known to
require CS initiation to mediate late 24 h CS (2, 21). The
isolated CS effector T cells were obtained by depleting B
cells from 4-d PCl immune-mixed LN and spleen cells
from WT mice using anti–CD-19 and complement treat-
ment or by negative magnetic selection (99% TCR  ).
As shown (2, 21, 22), the CS effector T cells could not
transfer either 2- or 24-h components of CS to ear-chal-
lenged nonimmune control WT recipients (Fig. 6 A, Group
A) without CS-initiating B-1 cells. However, when
B-depleted T cells were instead transferred to 1-d PCl im-
mune WT recipients, the 2- and 24-h CS were elicited
(Fig. 2 A, Group B). In contrast, the same CS effector T
cells failed to transfer 2- or 24-h CS responsiveness into 1-d
immune CD1d /  recipients (Fig. 6 A, Group C vs. B). The
1-d immune CD1d /  recipients (Fig. 6 A, Group C) may
not have generated sensitized CS-initiating B-1 cells, per-
haps due to their NKT cell deficiency. Similar results were
obtained with CS effector BALB/c T cells purified further
to 99% TCR   T cells by magnetic bead separation that
could not transfer either 2- or 24-h components of CS to
nonimmune BALB/c recipients (Fig. 6 B, Group A). How-
Figure 6. 4-d immune WT T cells fail to transfer CS to 1-d immune
NKT cell–deficient mice. (A) CD1d /  mice (Group C) and CD1d / 
WT controls (Group B) were skin sensitized and 1 d later received 4-d
PCl immune-isolated T cells from WT CD1d /  mice and then were ear
challenged 1 d later. The T cells were obtained by treating WT immune
cells with anti-CD19 plus complement. Nonimmune CD1d /  mice
(Group A) similarly received T cell transfers and were ear challenged.
Nonimmune CD1d /  (Group D) and CD1d /  mice (Group E) were
challenged but received no transfers. (B) J 18 /  mice (Group C) and
BALB/c WT controls (Group B) were contact sensitized and 1 d later
received 4-d PCl immune–isolated T cells from BALB/c mice and then
were ear challenged 1-d later. The T cells (99% TCR  ) were obtained
by magnetic separation. Nonimmune BALB/c mice (Group A) similarly
received T cell transfers and were ear challenged. Nonimmune J 18 / 
(Group D) and BALB/c mice (Group E) were challenged but received no
transfers. In A and B, the ear responses were measured at 2 and 24 h from
a representative experiment with four mice per group.Campos et al. 1791
ever, when these purified T cells were instead transferred to
1-d PCl immune WT BALB/c recipients, the 2 and 24 h
CS responses were elicited (Fig. 2 B, Group B). In impor-
tant contrast, the same purified CS effector T cells failed to
transfer 2- or 24-h CS responses into 1-d immune J 18 / 
recipients (Fig. 6 B, Group C vs. B). These data show that
1-d immune J 18 /  or CD1d /  recipients fail to gener-
ate CS initiation. We considered an alternate explanation
that NKT cell–deficient mice have reduced B-1 cells but
found no deficiency of peritoneal CD19 CD5  B-1 cell
numbers in these mice (not depicted).
IL-4 Treatment Reconstitutes Early and Late Components of
Defective CS in Sensitized CD1d /  and J 18 /  Mice.
We further evaluated whether defective CS initiation in
NKT cell–deficient mice was due to a lack of IL-4 by using
the same cell transfer protocol from Fig. 6. We attempted to
reconstitute CS in CD1d /  mice by injecting rIL-4 at the
time of sensitization (Fig. 7 A). Positive controls again
showed elicitation of 2- and 24-h CS (Fig. 7 A, Group A),
and there was defective 2- and 24-h CS in 1-d PCl immune
CD1d /  mice (Fig. 7 A, Group B). Systemic i.v. injection
of just 2 ng IL-4 during immunization did not cause signifi-
cant reconstitution of 24-h CS (Fig. 7 A, Group C). 20 ng
IL-4 led to reconstitution of 2- and 24-h CS responses (Fig.
7 A, Group D), whereas 200 ng of IL-4 reconstituted 2 h
CS, but the 24-h response was reduced compared with the
20 ng–treated group (Fig. 7 A. Group E vs. D, right).
We similarly attempted CS reconstitution by injecting IL-4
at the time of sensitization in J 18 /  mice using the pro-
tocol in Fig. 6 B in which we transferred WT magnetic-iso-
lated purified CS effector T cells (Fig. 7 B). As before, posi-
tive controls showed elicitation of 2- and 24-h CS (Fig. 7 B,
Group B), but CS responses were defective in 1-d PCl im-
mune J 18 /  mice (Fig. 4 B, Group C). Again, systemic
injection of 20 ng IL-4 i.v. during immunization led to
complete reconstitution of 2- and 24-h CS in these 1-d PCl
immune J 18 /  mice (Group D). These results suggest that
injection of IL-4 at immunization restored impaired CS ini-
tiation for eventual recruitment of effector T cells in immu-
nized NKT cell–deficient CD1d /  and J 18 /  mice.
Sensitized CD1d /  Mice Have Intact Immunized CS Effec-
tor T Cells: Reconstitution with Immune B-1 Cells. The
above transfer experiments did not examine if CS effector
T cells were intact in NKT cell–deficient mice. Thus, im-
munized CD1d /  mice were used as cell transfer recipi-
ents at day 4 when effector T cells become fully activated
(1, 20, 21). Thus, in a new experiment, we tested if failure
of CS initiation in NKT cell–deficient mice was due to an
inability to activate B-1 cells. We transferred activated B-1
cells from 1-d PCl-immune WT donors, and the 4-d im-
mune recipients were challenged 1 d later. Positive control
4-d actively immunized CD1d /  mice had normal elicita-
tion of 2- and 24-h CS compared with nonimmune con-
trols (Fig. 8, Group A vs. F). Further, as shown previously
(Fig. 1 A) 4-d immune CD1d /  mice had absent 2-h CS
and inhibited 24-h CS (Fig. 8, Group A vs. B vs. E). Re-
Figure 8. Immune B-1 cells from CD1d /  mice reconstitute 2 and 24 h
CS in PCl-sensitized CD1d /  mice. WT CD1d /  controls (Group A)
and CD1d /  mice (Groups B–D) were contact sensitized. Then, 3 d
later Group C received 1-d immune cells from CD1d /  mice, and
Group D received sorted 1-d immune CD19 CD5  B-1 cells from
CD1d /  mice. On day 4, all groups were ear challenged. Nonimmune
CD1d /  mice (Group E) and CD1d /  mice (Group F) were also ear
challenged. Group G is nonimmune WT mice that just received 1-d PCl
immune cells. Ear swelling was measured at 2 and 24 h, and the results are
from a representative experiment with four mice per group; *P   0.05;
**P   0.01.
Figure 7. IL-4 reconstitutes early and late CS responses in NKT cell–
deficient mice. (A) WT 1-d PCl immune mice (Group A) were compared
with 1-d immune CD1d /  mice (Group B) as recipients of 4-d PCl
immune T cells from CD1d /  mice. WT immune mice elicited 2 and
24 h CS (Group A), whereas the CD1d /  mice did not (Group B).
Groups C–E are identical to Group B. However, these 1-d immune
CD1d /  mice that received isolated immune T cells also were injected
with different doses of rIL-4 during immunization. *P   0.05; **P  
0.001. (B) WT BALB/c 1-d active PCl immune mice (Group B) were
compared with 1-d immune J 18 /  (Group C) as recipients of 4-d PCl
immune magnetic-separated T cells from BALB/c mice. Group D is
identical to Group C, but 20 ng i.v. of IL-4 was injected during immuni-
zation of the 1-d immune J 18 /  recipient mice. In A and B, the results
are mean   SE from four mice per group.V 14i NKT Cells Initiate Contact Sensitivity 1792
markably, transfer of WT 1-d immune cells that contained
sensitized B-1 cells into 4-d immune CD1d /  recipients
largely reconstituted 2- and 24-h CS (Fig. 8, Group C vs.
B). Also, 98% purified B-1 cells from the 1-d PCl immune
donors similarly reconstituted both early 2- and late 24-h
components of CS (Fig. 8, Group D vs. B).
These results confirmed the competence of 4-d PCl-
immune CD1d /  mice to generate CS effector T cells (Fig.
8, Groups C and D) that in this case were recruited nor-
mally to mediate 24-h CS, when CS initiation was pro-
vided by transferred WT 1-d immune cells (Group C) or
by purified B-1 cells (Group D). Control Group G shows
that 1-d PCl immune cells from WT mice mediated 2-h,
but not the 24-h ear swelling, because CS effector T cells
had not yet developed (1, 20, 21). This documents that 24-h
CS responses obtained in Fig. 8, Groups C and D, were
not from transferred 1-d immune cells alone.
NKT Cell–deficient Mice Have Impaired Specific IgM Re-
sponses. Results suggest that soon after CS immunization,
V 14i NKT cell–derived IL-4 activates B-1 cells to pro-
duce specific IgM. Thus, defective CS initiation in NKT
cell–deficient mice may be explained by defective produc-
tion of specific initiating IgM antibodies by the B-1 cells.
To test this, we used ELISPOT to evaluate numbers of
spleen cells producing anti-TNP IgM antibodies in J 18 / 
compared with WT BALB/c mice after PCl immuniza-
tion. We found a smaller number of anti-TNP IgM–pro-
ducing cells 4 d after PCl skin immunization in the J 18 / 
mice compared with WT BALB/c (Fig. 9) when 2- and
24-h ear responses were defective. Similar results were ob-
tained with PCl immunized CD1d /  vs. WT 129 S3/
SvImJ mice (not depicted). These finding of impaired pro-
duction of anti-TNP–specific IgM antibodies after CS in
both strains of iNKT cell–deficient mice reinforced the
idea that V 14i NKT cells are needed to activate B-1 cells
to produce CS-initiating IgM antibodies.
Figure 9. NKT cell–deficient mice have an impaired specific IgM re-
sponse. J 18 /  and WT BALB/c mice were PCl skin immunized or
sham immunized, and 4 d later their splenocytes were harvested and incu-
bated in vitro to measure numbers of anti-TNP IgM-producing cells
using an ELISPOT assay. The results are pooled consisting of seven mice
per group from three experiments. The background IgM anti-BSA responses,
obtained by counting number of spots in BSA-coated plates, were sub-
tracted, as were responses in sham immune mice of each strain.
Figure 10. Summary schema:
early activation of liver V 14i
NKT cells leads to initiation of
systemic CS immunity. Cutane-
ous sensitization with PCl (TNP-
Cl) is postulated to cause local
release from the site of immuni-
zation of diverse ligands that act
in three directions. First, rapidly
after immunization uncharacter-
ized glycolipid ligands stimulate
V 14i NKT cells likely in the
liver to produce IL-4. Second,
soluble hapten–self-protein and
peptide complexes formed by
conjugation of the hapten are
rapidly released systemically. It is
postulated that together the
V 14i NKT cell-derived IL-4
and Ag hapten–self complexes
coactivate the B-1 B cells to
produce hapten-specific IgM
antibodies that circulate within
1 d after sensitization. Third,
self-peptides complexed with
surface MHC molecules of local
APC, such as Langerhans cells,
are conjugated with the immu-
nizing hapten to form TNP-
peptide–MHC complexes that
induce maturation and activation of CS effector memory T cells in the LNs within 4 d after immunization. Subsequently, after secondary ear Ag challenge
to elicit CS the local B-1–derived IgM antibodies form complexes with the challenge TNP Ag–self complexes. This activates local complement to generate
C5a at the Ag challenge site, leading to release of vasoactive mediators from mast cells that alter the local endothelium, allowing recruitment of the Ag/MHC-
restricted CS effector T cells to mediate the late classical 24-h CS response.Campos et al. 1793
Together (Fig. 10), the data indicate that very early after
PCl skin sensitization there is rapid stimulation of hepatic
V 14i NKT cells required to activate CS-initiating B-1 cells
to produce IgM antibodies, likely via production of IL-4.
Discussion
We have shown for the first time that V 14i NKT cells
are required in CS, which is a prototype of acquired in
vivo T cell–mediated immunity. These findings reinforce
previous connections we established between the initiation
of CS elicitation and other components of the innate im-
mune system (2, 3, 6, 23–25). A new aspect is the very
early and rapid stimulation of the V 14i NKT cell subset
within 1 h of immunization that induces initiating B-1 cell
responses within 1 d and leads to subsequent recruitment of
CS effector   T cells to enable elicitation of classical 24 h
CS. Moreover, the unique early and preferential expansion
of hepatic V 14i NKT cells after contact sensitization sug-
gests that cutaneous CS immunization induced rapid and
previously unrecognized systemic effects on iNKT cells, in
addition to the known Ag uptake by APC to generate the
classical CS effector T cells.
NKT Cell Involvement in CS Initiation. It is known that
only activation of V 14i NKT cells via their TCR, by ei-
ther exogenous nonspecific  -GalCer or by anti-CD3, rap-
idly results in production of high levels of serum IL-4 (26–
28). Therefore, we postulate that V 14i NKT cells are
activated through their TCR to rapidly release IL-4 after
contact skin immunization, which together with specific
TNP-Ag released systemically from the contact skin sensi-
tization site (29) coactivates B-1 cells within 1 d of immu-
nization (2, 21, 30, 31). Finding impaired CS responses in
two different strains of NKT cell–deficient mice provided
strong evidence for a role of V 14i NKT cells in CS.
Reconstitution of defective CS in J 18 /  mice by
transferring nonimmune WT or V 14 transgenic hepatic
or splenic MNC containing V 14i NKT cells pointed to
involvement of these cells in CS. Importantly, the role of
IL-4 derived from V 14i NKT cells was demonstrated spe-
cifically by failure of CS reconstitution using LMNCs from
IL-4 /  mice. The role of V 14i NKT cells was confirmed
by the lack of reconstitution of CS with LMNCs from
NKT cell–deficient J 18 /  mice.
Although V 14i NKT cells can also rapidly release high
levels of IFN-  (28, 32), this probably is not involved in
early activation of CS-initiating B-1 cells. When we trans-
ferred LMNCs from IFN-  /  mice 1 d before immuniza-
tion of J 18 /  mice, there was a full reconstitution of the
early 2-h response. However, it remains possible that
V 14i NKT cells release both IFN-  and IL-4 in CS but
that IL-4 predominantly plays an early facilitating role by
activating B-1 cells.
Systemic treatment with 20 ng of IL-4 at the time of
sensitization reconstituted CS responses in immunized
CD1d /  and J 18 /  mice. Moreover, we further tested
the postulate that V 14i NKT cell–derived IL-4 is needed
to activate CS-initiating B-1 cells. We showed that down-
stream-acting immune B-1 cells from contact-sensitized
WT mice were able to reconstitute elicitation of CS in
NKT cell–deficient CD1d /  or J 18 /  mice. This con-
firmed our hypothesis that an early wave of IL-4 release
from V 14i NKT cells rapidly after contact sensitization
likely activates CS-initiating B-1 cells. Therefore, the re-
quirement for V 14i NKT cells was circumvented by pro-
viding the missing NKT cells, or IL-4, or immune B-1
cells presumably already activated by IL-4 in the immu-
nized WT donors.
Others have shown that systemic injection of  -GalCer
rapidly activates V 14i NKT cell production of IL-4 to in-
duce B cell activation (28). Our demonstration of NKT
cell activation of B-1 cells to initiate CS expands the B cell
helper role of NKT cells via IL-4 shown with Th2 cell–
dependent B-2 cell IgE responses in murine asthma (33,
34), in an IL-18–dependent in vitro model (35), and in a
human system (36).
Activation of V 14i NKT Cells by Cutaneous CS. Early
increases in liver V 14i NKT cells after PCl skin sensitiza-
tion provided strong direct evidence for in vivo participa-
tion of V 14i NKT cells early postimmunization in CS. In
addition, the time course of hepatic V 14i NKT cell
changes after PCl sensitization was very different from i.v.
injection of  -GalCer. Cutaneous sensitization caused a
rapid onset and steady increase in V 14i NKT cells fol-
lowed by a slow return to basal levels by 24 h, perhaps due
to weaker activation with no subsequent apoptosis. In con-
trast,  -GalCer induced a smaller rapid rise and then severe
reduction that persisted for 24 h. This may be due to
TCR-mediated activation–induced apoptosis (37, 38) or
down modulation of V 14 TCR.
Although V 14i NKT cells were increased in the liver
after CS, no similar increases in the spleen, LNs, or perito-
neal cavity were detected by tetramer staining. This result
showing a specific association of activation of liver NKT
cells with skin sensitization was unexpected. Perhaps V 14i
NKT cells from other distant sites also are activated after
contact immunization. Note that transferred splenocytes
from V 14 transgenic mice could also reconstitute CS in
J 18 /  mice. Thus, it cannot be excluded that effective
activation of V 14i NKT cells from these other sites for
participation in CS is not always detected by tetramer stain-
ing. Conversely, the V 14i NKT cells, or the APC in the
liver, may have specific properties that could result in pref-
erential activation after skin sensitization.
Postulated Mechanisms of V 14i NKT Cell Activation in
CS. Studies of CS may lead to eventual identification of
natural endogenous CD1d-binding ligands for the TCR of
V 14i NKT cells. During PCl skin contact sensitization,
there may be release from the skin of endogenous glycolip-
ids that may disperse systemically, particularly to the liver.
These released endogenous ligands may bind CD1d on
APC and activate V 14i NKT cells to cause rapid produc-
tion of IL-4. As a parallel, it is established in CS that skin-
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from contact immunization rapidly are dispersed through-
out the body by the systemic circulation and influence the
overall immune response (29).
The stimulus for V 14i NKT cell activation in CS may
be less intense compared with the artificial ligand  -Gal-
Cer. Indeed, in vivo administration of  -GalCer leads to
hepatic damage within 1 d (38) and in vivo treatment
with anti-CD3  and IL-12–induced NKT cell apoptosis
in the liver (39). Hence, physiological NKT cell activa-
tion, such as in CS, may be less powerful without apopto-
sis and depletion. Another difference between CS and
 -GalCer effects on V 14i NKT cells is the route of ex-
posure, since  -GalCer was injected i.v. and PCl applied
by contact skin painting.
Comparison of NKT Cell Involvement in CS to Other Sys-
tems. There is a significant difference between our data
showing involvement of V 14i NKT cells in CS and their
participation in several other systems (40–49). In most of
these instances, V 14i NKT cells are triggered by systemic
injections of  -GalCer, which is an exogenous ligand of
CD1d and the NKT cell V 14J 18 TCR. In contrast, we
have shown that cutaneous immunization alone rapidly ac-
tivates liver V 14i NKT cells via presumed release of en-
dogenous ligands different from but analogous to exoge-
nous   -GalCer. Some infections may also generate
endogenous activators that can deplete NKT cells (50).
The unique participation of V 14i NKT cells in CS sug-
gests similar positive involvement of V 14i NKT cells in
other important responses may also be uncovered, as is true
in allergic murine asthma models (33, 34).
Fig. 10 summarizes the processes we postulate after re-
lease of endogenous glycolipids that trigger V 14i NKT
cells to coactivate B-1 cells. It is noteworthy that CS is a
paradigm for other T cell–dependent in vivo immune
DTH-like mechanisms that mediate numerous diseases.
Similar mechanisms to those we have described in CS may
underlie protection in infections, tumors, autoimmune dis-
eases, allergies, and asthma which also involve recruitment
of T cells into the tissue site.
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